8 results about "Nucleic acid binding protein" patented technology

The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with protease-conditional recombinase (hereinafter “ProRec”) activity. Namely a new cre recombinase pro enzyme, compositions / kit and sensors comprising the cre recombinase pro enzyme of the present disclosure. Namely, a cre recombinase pro-enzyme, for identifying and quantifying proteolytic activity in a disease or an infection, comprising intein mediated circularization, a flip-excision cassette comprising an output reporter and / or effector protein; a linker sequence cleavable by a protease.

The present disclosure relates to lipid nanoparticles for delivery of RNA, the lipid nanoparticle comprising therein a nucleic acid-binding protein or peptide (e.g., a RNA-binding protein or peptide) bound to the RNA, and uses thereof.

The application provides a method for separating nucleic acid binding proteins in solid tissue cells, and the method comprises the following steps: step S1, preparing solid tissue into a cell suspension 1; step S2, cross-linking the cell suspension 1 by using a cross-linking agent to form a cell suspension 2 with nucleic acid-NABPs complexes; step S3, lysing red blood cells in the cell suspension 2 of step S2 to remove high-abundance protein interference; step S4, after the cells treated in step S3 are lysed by using an organic reagent, the nucleic acid-NABPs complexes in the solid tissue cells are selectively enriched by using affinity chromatography; and step S5, after the nucleic acid-NABPs complexes obtained in step S4 are de-cross-linked, nucleic acid binding proteins (NABPs) in the solid tissue cells are obtained.

Methods and compositions for purifying a nucleic acid preparation. The methods include contacting a nucleic acid preparation including single-stranded ribonucleic acid (ssRNA) with a double-stranded ribonucleic acid binding protein (dsRBP) that specifically binds to double-stranded ribonucleic acid (dsRNA) and is optionally immobilized on a solid support before or after the dsRBP-dsRNA complex is formed to remove dsRNA from a mixed nucleic acid preparation.

Methods for proximity ligation of nucleic acids complexed with nucleic acid binding proteins using transposase to cleave the nucleic acids, and ligating the products are provided. Compositions for said methods are further provided.

The invention discloses a pyrazolone compound, a pharmaceutical composition containing the pyrazolone compound and application of the pyrazolone compound and the pharmaceutical composition. The pyrazolone compound is a compound shown in a general formula I or a tautomer, a raceme, a meso-raceme, an enantiomer, a diastereoisomer and pharmaceutically acceptable salt of the compound. The pyrazolone compound provided by the invention can inhibit a Z-type nucleic acid binding protein 1 (ZBP1) signal channel, and has an application prospect in treatment of diseases related to ZBP1 protein functions.

The present disclosure provides a single-chain binding protein T4 gp32 mutant and its application. The present disclosure screens T4 gp32 protein variants by using point mutation technology, and the affinity and stability of the mutant to DNA are obviously improved compared with the wild type. The T4 gp32 protein variant screened by the present disclosure can significantly improve the efficiency of the RPA reaction, greatly shorten the reaction time of the RPA reaction, and make it more suitable for basic laboratories and on-site rapid nucleic acid detection.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function through spatiochemical and spatiotemporal control over intracellular regulatory protein networks at the level of expressed gene products of nucleic acid-binding protein (NABP) genes. Subpopulation-specific cytoactive agents of the invention are used in therapeutic compositions that up- or downregulate disease-associated intracellular regulatory protein genes at the RNA and protein level for prevention and treatment of plant, animal and human diseases. Applications in human clinical medicine include biopharmaceutical preparations and associated treatment methods for genetic, degenerative, neurological, cellular and immune disorders resulting from dysregulation of endogenous NABP regulatory networks. Therapeutic compositions designed or selected for use in plants and nonhuman animals are applied to the fields of agriculture and veterinary medicine. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions across fields. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first subpopulation of a cellular protein or therapeutic target without substantially altering the activity of at least a second subpopulation of the cellular protein or therapeutic target.